Grants and Contracts Details
TITLE: A PHASE Ill, MUL TICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB FOR PATIENTS WITH NEWLY-DIAGNOSED STAGE Ill OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER Objectives and Endpoints This study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumab administered with paclitaxel+carboplatin+bevacizumab compared with placebo+ paclitaxel+carboplatin+ bevacizumab in patients with newly-diagnosed, untreated ovarian, fallopian tube, and/or primary peritoneal cancer.
|Effective start/end date||11/29/17 → 7/13/23|
- Gynecological Oncology Group Foundation Incorporated: $272,309.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.